Cancer Research Cancer Epigenetics  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hendriks, B. S.
Right arrow Articles by Lauffenburger, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hendriks, B. S.
Right arrow Articles by Lauffenburger, D.
[Cancer Research 63, 1130-1137, March 1, 2003]
© 2003 American Association for Cancer Research


Tumor Biology

Coregulation of Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 (HER2) Levels and Locations

Quantitative Analysis of HER2 Overexpression Effects1

Bart S. Hendriks, Lee K. Opresko, H. Steven Wiley and Douglas Lauffenburger2

Department of Chemical Engineering [B. S. H., D. L.], Biological Engineering Division [D. L.], and Center for Cancer Research [D. L.], Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, and Environmental and Health Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99352 [L. K. O., H. S. W.]

Elevated expression of human epidermal growth factor receptor 2 (HER2) is known to alter cellsignaling and behavioral responses implicated in tumor progression. However, multiple diverse mechanisms may be involved in these overall effects, including signaling by HER2 itself, modulation of signaling by epidermal growth factor receptor (EGFR), and modification of trafficking dynamics for both EGFR and HER2. Because these processes are so tightly interrelated, the net effect of HER2 overexpression is difficult to reliably attribute to any single particular mechanism. To take an important first step toward dissecting the effects of HER2 overexpression on cell responses in terms of the various specific underlying mechanisms, we have developed and validated a quantitative model of the relevant trafficking processes. We then use our model for successful prediction of EGFR and HER2 level and location changes attributable to HER2 overexpression in 184A1 human mammary epithelial cells expressing a series of HER2 levels by retroviral infection. Model predictions are based on our independent experimental measurement of key trafficking parameters for both EGFR and HER2. In terms of trafficking processes, HER2 overexpression reduces the EGFR internalization rate constant and increases the fraction of EGFR recycled. Consequently, our model successfully predicts that HER2 increases the overall level of activated EGFR by both enhancing its recycling and reducing its internalization, but it increases activated EGFR localization at the cell surface almost solely by its reduction of internalization. Furthermore, the model also successfully predicts the effects of monoclonal antibody 2C4, which interferes with HER2/EGFR heterodimerization, on EGFR and HER2 levels and compartmental locations. We anticipate that this model should ultimately be useful in parsing the relative contributions of direct effects of HER2 via signaling vis-a-vis indirect effects of HER2 via modification of EGFR signaling.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
E. J. Joslin, L. K. Opresko, A. Wells, H. S. Wiley, and D. A. Lauffenburger
EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation
J. Cell Sci., October 15, 2007; 120(20): 3688 - 3699.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Wolf-Yadlin, S. Hautaniemi, D. A. Lauffenburger, and F. M. White
Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks
PNAS, April 3, 2007; 104(14): 5860 - 5865.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. J. Lazzara and W. M. Deen
Model of albumin reabsorption in the proximal tubule
Am J Physiol Renal Physiol, January 1, 2007; 292(1): F430 - F439.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L. A. Scheving, L. Zhang, M. C. Stevenson, E. S. Kwak, and W. E. Russell
The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling.
Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G16 - G25.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
Y. Zhang, A. Wolf-Yadlin, P. L. Ross, D. J. Pappin, J. Rush, D. A. Lauffenburger, and F. M. White
Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules
Mol. Cell. Proteomics, September 1, 2005; 4(9): 1240 - 1250.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. S. Hendriks, G. Orr, A. Wells, H. S. Wiley, and D. A. Lauffenburger
Parsing ERK Activation Reveals Quantitatively Equivalent Contributions from Epidermal Growth Factor Receptor and HER2 in Human Mammary Epithelial Cells
J. Biol. Chem., February 18, 2005; 280(7): 6157 - 6169.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
C. D. Austin, A. M. De Maziere, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman, and R. H. Scheller
Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin
Mol. Biol. Cell, December 1, 2004; 15(12): 5268 - 5282.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
A. M. Hommelgaard, M. Lerdrup, and B. van Deurs
Association with Membrane Protrusions Makes ErbB2 an Internalization-resistant Receptor
Mol. Biol. Cell, April 1, 2004; 15(4): 1557 - 1567.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. Tikhomirov and G. Carpenter
Ligand-induced, p38-dependent Apoptosis in Cells Expressing High Levels of Epidermal Growth Factor Receptor and ErbB-2
J. Biol. Chem., March 26, 2004; 279(13): 12988 - 12996.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. S. Hendriks, L. K. Opresko, H. S. Wiley, and D. Lauffenburger
Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis: DISTRIBUTION OF HOMO- AND HETERODIMERS DEPENDS ON RELATIVE HER2 LEVELS
J. Biol. Chem., June 20, 2003; 278(26): 23343 - 23351.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.